Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
142 hedge funds and large institutions have $1.1B invested in Alder Biopharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 14 closing their positions.
75% more capital inflows, than outflows
Capital inflows: $175M | Capital outflows: $100M
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
11% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.54% less ownership
Funds ownership: 106.38% → 104.84% (-1.5%)
2% less funds holding
Funds holding: 145 → 142 (-3)
16% less call options, than puts
Call options by funds: $742K | Put options by funds: $882K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$87.2M |
| 2 |
Redmile Group
San Francisco,
California
|
+$21.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.6M |
| 4 |
AG
Artal Group
Luxembourg
|
+$6.64M |
| 5 |
Pictet Asset Management (UK)
London,
United Kingdom
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM Health Sciences
San Francisco,
California
|
-$41.4M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.7M |
| 3 |
Clough Capital Partners
Boston,
Massachusetts
|
-$9.7M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$6M |
| 5 |
Eventide Asset Management
Boston,
Massachusetts
|
-$3.01M |
ALDR Hedge Fund Activity: Q1 2017 in Review
142 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q1 2017, worth a combined $1.1B — down 1.2% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALDR positions and 14 closed out — a net gain of 4 holders — while 52 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $87.2M. The largest seller was PFM Health Sciences, cutting an estimated $41.4M.
- 142 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q1 2017, down from 145 in Q4 2016.
- Funds reported $1.1B of Alder Biopharmaceuticals stock for Q1 2017, down 1.2% quarter-over-quarter.
- 18 funds opened new Alder Biopharmaceuticals positions in Q1 2017 and 14 closed out, a net change of +4 holders.
- The largest Alder Biopharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $87.2M added.
- The largest Alder Biopharmaceuticals seller in Q1 2017 was PFM Health Sciences, an estimated $41.4M sold.
Based on aggregated 13F filings for Q1 2017.